Evidence map›Paper›PMID 34335281›Full record

ArticleFrontiers in pharmacology2021

Corrigendum: PKM2-Induced the Phosphorylation of Histone H3 Contributes to EGF-Mediated PD-L1 Transcription in HCC.

Xiao Wang, Chao Liang, Xin Yao, Ruo-Han Yang, Zhan-Sheng Zhang, Fan-Ye Liu, Wen-Qi Li, Shu-Hua Pei, Jing Ma, Song-Qiang Xie and 1 more

Open access · goldAbstract readPublished Erratum
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Xiao WangInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Chao LiangInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Xin YaoInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Ruo-Han YangInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Zhan-Sheng ZhangInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Fan-Ye LiuInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Wen-Qi LiInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Shu-Hua PeiInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Jing MaInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Song-Qiang XieInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Dong FangInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Henan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fphar.2020.577108.].

Indexed as

epidermal growth factorhepatocellular carcinomahistone H3programmed death-ligand-1pyruvate kinase isoform M2

Identifiers

PMID34335281
PMCPMC8320321
OpenAlexW3183863734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.